Annette von Delft
M.D, Ph.D.
Translational Scientist
Annette trained as a medical doctor at University of Leipzig (Germany) and received her D.Phil in Clinical Medicine at the University of Oxford in 2010. Her project focused on HCV T cell immunology and vaccine development under the supervision of Prof Eleanor Barnes. She then completed her medical foundation programme at Oxford University Hospitals.
Annette joined the BRC team in 2018 as a translational scientist with a focus on inflammation and immunity. She is currently involved in a range of projects in immunology, infectious disease and neuroscience.
Recent publications
-
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Journal article
Achdout H. et al, (2020)
-
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Journal article
Esposito I. et al, (2020), Sci Transl Med, 12
-
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
Journal article
von Delft A. et al, (2018), Vaccine, 36, 313 - 321
-
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
Journal article
Ansari MA. et al, (2017), Nat Genet, 49, 666 - 673
-
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
Journal article
Swadling L. et al, (2016), Vaccines (Basel), 4